These findings suggest that SOX9 drives lymphoma progression through the DHCR24 and cholesterol biosynthesis pathways, and the SOX9‐DHCR24‐cholesterol biosynthesis axis could serve as a novel therapeutic target for DLBCLs [141]. The gene discussed is SOX9; the disease is lymphoma.